Synnovation Therapeutics
Pramod Thekkat is an accomplished biomedical researcher with extensive experience in immunotherapy and targeted cancer therapy. Currently serving as a Principal Investigator at Synnovation Therapeutics since January 2024, Pramod previously held the role of Senior Scientist at Proteovant Therapeutics from December 2021 to December 2023, and served as a Research Expert at Incyte for over six years. Pramod's expertise encompasses the execution of key experiments for novel target identification, development and optimization of immunoassays, and support for FDA-approved campaigns. Earlier positions include Scientist I at Novartis Institutes for BioMedical Research and roles at Cold Spring Harbor Laboratory and Stanford University, with a solid academic foundation from Western Michigan University where a Master of Science in Biochemistry and Molecular Biology was obtained.
This person is not in any teams
Synnovation Therapeutics
Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers.It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.